Brokerages Set Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Target Price at $30.00

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) has received a consensus recommendation of “Moderate Buy” from the nine research firms that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have issued a buy recommendation on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $30.00.

Several research analysts recently weighed in on OLMA shares. Oppenheimer boosted their price objective on shares of Olema Pharmaceuticals from $22.00 to $45.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 18th. Citigroup lifted their target price on Olema Pharmaceuticals from $20.00 to $21.00 and gave the company a “buy” rating in a research note on Tuesday, August 12th. JPMorgan Chase & Co. upped their price target on Olema Pharmaceuticals from $29.00 to $32.00 and gave the company an “overweight” rating in a research note on Tuesday, November 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Olema Pharmaceuticals in a research report on Wednesday, October 8th. Finally, The Goldman Sachs Group boosted their price objective on Olema Pharmaceuticals from $18.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, November 21st.

Olema Pharmaceuticals Stock Performance

Shares of NASDAQ:OLMA opened at $28.12 on Friday. The business has a fifty day moving average of $11.51 and a 200-day moving average of $7.38. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.03 and a current ratio of 8.03. Olema Pharmaceuticals has a twelve month low of $2.86 and a twelve month high of $29.51. The firm has a market cap of $1.93 billion, a PE ratio of -15.04 and a beta of 2.07.

Olema Pharmaceuticals (NASDAQ:OLMA) last announced its earnings results on Monday, November 10th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.05). On average, equities research analysts predict that Olema Pharmaceuticals will post -2.33 EPS for the current fiscal year.

Insider Buying and Selling at Olema Pharmaceuticals

In related news, Director Cyrus Harmon sold 3,086 shares of the stock in a transaction that occurred on Thursday, September 18th. The shares were sold at an average price of $8.32, for a total value of $25,675.52. Following the transaction, the director directly owned 117,028 shares in the company, valued at $973,672.96. This represents a 2.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold 25,000 shares of company stock worth $204,841 over the last ninety days. Insiders own 16.36% of the company’s stock.

Institutional Trading of Olema Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. Ameritas Investment Partners Inc. lifted its stake in shares of Olema Pharmaceuticals by 55.4% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,080 shares of the company’s stock valued at $26,000 after purchasing an additional 2,168 shares during the period. Farther Finance Advisors LLC increased its holdings in Olema Pharmaceuticals by 602.9% in the second quarter. Farther Finance Advisors LLC now owns 6,839 shares of the company’s stock valued at $29,000 after purchasing an additional 5,866 shares during the last quarter. FNY Investment Advisers LLC lifted its stake in Olema Pharmaceuticals by 100.0% in the second quarter. FNY Investment Advisers LLC now owns 10,000 shares of the company’s stock valued at $42,000 after buying an additional 5,000 shares during the period. Quarry LP acquired a new position in Olema Pharmaceuticals in the first quarter valued at about $45,000. Finally, Alpine Global Management LLC bought a new position in Olema Pharmaceuticals during the first quarter worth about $52,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.